D. De Maeseneer Archives - Page 3 of 3

O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY

BJMO - volume 12, issue 3, february 2018

B. De Laere PhD, Markus Mayrhofer , T. Whitington , P-J. Van Dam MD, P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , Nick Beije , Inge De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , Lien Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , Jurgen Del-Favero , S. Sleijfer , A. Uhlen , Jeffrey Yachnin , S. Van Laere PhD, Henrik Grönberg , Johan Lindberg , L. Dirix MD

O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer

BJMO - 2017, issue 3, february 2017

B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD

Attacking the androgen receptor pathway in prostate cancer

BJMO - volume 7, issue 4, september 2013

C. Van Praet MD, D. De Maeseneer MD, N. Lumen MD, PhD, S. Rottey MD, PhD

Summary

Since the 1940’s the androgen receptor has been the main target for systemic therapy in prostate cancer. Classic hormonal therapy aims at lowering serum testosterone levels or block the androgen receptor ligand-binding domain. Despite disease progression, castration-resistant prostate cancer remains predominantly androgen-driven as novel secondary hormonal therapy with abiraterone acetate or enzalutamide has demonstrated increased overall survival. Promising androgen synthesis inhibitors (orteronel, galeterone), androgen receptor inhibitors (ARN-509, EPI-001, AZD3514) and heat-shock protein modulators are under investigation. Given the upcoming arsenal of systemic therapies and the molecular heterogeneity of castration-resistant prostate cancer, patient-tailored therapy strategies are being explored.

(BELG J MED ONCOL 2013;7(3):111–8)